hrp0097p1-310 | Growth and Syndromes | ESPE2023

Persistence to growth hormone treatment and clinical characteristics of paediatric patients with growth hormone deficiency: A retrospective database study

Mori Jun , Sato Yukihito , Dateki Sumito

Background: For many years, raising awareness on early referral to endocrinologist, early diagnosis, and treatment continuation for paediatric patients with growth hormone deficiency (GHD) has been continued in Japan. However, the current status of trends in age at diagnosis and of treatment continuation have not been fully clarified.Aim: The aim of this study is to estimate the persistence to growth hormone treatment (G...

hrp0097fc11.5 | GH and IGFs | ESPE2023

Effective GH Replacement with Once-weekly Somapacitan in Japanese Children with GH Deficiency: 2-year Results from REAL4

Ohata Yasuhisa , Mori Jun , Fujisawa Yasuko , Sato Yukihito , Röhrich Sebastian , Højby Rasmussen Michael , Beck Bang Rikke , Horikawa Reiko

Growth hormone deficiency (GHD) in children results in reduced adult height. Children with GHD typically require daily subcutaneous (s.c.) injections of growth hormone (GH). Daily injections are burdensome for both patients and their caregivers and reduced adherence negatively impacts clinical outcomes. Somapacitan (Novo Nordisk) is a long-acting reversible albumin-binding human GH derivative in development for once-weekly s.c. administration in children with GHD, aiming to ov...